Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1972 4
1973 4
1974 3
1975 1
1977 3
1978 1
1981 1
1982 1
1985 1
1987 1
1988 1
1989 1
1990 1
1993 2
1994 3
1995 3
1996 2
1998 2
2003 3
2005 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 3
2012 3
2013 6
2014 14
2015 9
2016 15
2017 16
2018 8
2019 7
2020 3
2021 3
2022 3
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.
Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, Casero D, Courtney H, Gonzalez A, Graeber TG, Hall AB, Lake K, Landers CJ, Mallick H, Plichta DR, Prasad M, Rahnavard G, Sauk J, Shungin D, Vázquez-Baeza Y, White RA 3rd; IBDMDB Investigators; Braun J, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, Petrosino JF, Stappenbeck TS, Winter HS, Clish CB, Franzosa EA, Vlamakis H, Xavier RJ, Huttenhower C. Lloyd-Price J, et al. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Epub 2019 May 29. Nature. 2019. PMID: 31142855 Free PMC article. Review.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Sandborn WJ, et al. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. N Engl J Med. 2012. PMID: 23075178 Free article. Clinical Trial.
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis.
Canales-Herrerias P, Uzzan M, Seki A, Czepielewski RS, Verstockt B, Livanos AE, Raso F, Dunn A, Dai D, Wang A, Al-Taie Z, Martin J, Laurent T, Ko HM, Tokuyama M, Tankelevich M, Meringer H, Cossarini F, Jha D, Krek A, Paulsen JD, Taylor MD, Nakadar MZ, Wong J, Erlich EC, Mintz RL, Onufer EJ, Helmink BA, Sharma K, Rosenstein A, Ganjian D, Chung G, Dawson T, Juarez J, Yajnik V, Cerutti A, Faith JJ, Suarez-Farinas M, Argmann C, Petralia F, Randolph GJ, Polydorides AD, Reboldi A, Colombel JF, Mehandru S. Canales-Herrerias P, et al. Among authors: yajnik v. Sci Immunol. 2024 Apr 19;9(94):eadg7549. doi: 10.1126/sciimmunol.adg7549. Epub 2024 Apr 19. Sci Immunol. 2024. PMID: 38640252 Free PMC article.
Challenges in IBD Research: Novel Technologies.
Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F. Dhyani M, et al. Among authors: yajnik v. Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S24-S30. doi: 10.1093/ibd/izz077. Inflamm Bowel Dis. 2019. PMID: 31095703 Free PMC article. Review.
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis.
Canales-Herrerias P, Uzzan M, Seki A, Czepielewski RS, Verstockt B, Livanos A, Raso F, Dunn A, Dai D, Wang A, Al-Taie Z, Martin J, Ko HM, Tokuyama M, Tankelevich M, Meringer H, Cossarini F, Jha D, Krek A, Paulsen JD, Nakadar MZ, Wong J, Erlich EC, Onufer EJ, Helmink BA, Sharma K, Rosenstein A, Chung G, Dawson T, Juarez J, Yajnik V, Cerutti A, Faith J, Suarez-Farinas M, Argmann C, Petralia F, Randolph GJ, Polydorides AD, Reboldi A, Colombel JF, Mehandru S. Canales-Herrerias P, et al. Among authors: yajnik v. bioRxiv [Preprint]. 2023 Jan 20:2023.01.19.524731. doi: 10.1101/2023.01.19.524731. bioRxiv. 2023. Update in: Sci Immunol. 2024 Apr 19;9(94):eadg7549. doi: 10.1126/sciimmunol.adg7549 PMID: 36711839 Free PMC article. Updated. Preprint.
ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.
Jairath V, Yarur A, Osterman MT, James A, Balma D, Mehrotra S, Yang L, Yajnik V, Qasim Khan RM. Jairath V, et al. Among authors: yajnik v. Clin Gastroenterol Hepatol. 2024 May;22(5):1077-1086.e13. doi: 10.1016/j.cgh.2023.10.029. Epub 2023 Nov 10. Clin Gastroenterol Hepatol. 2024. PMID: 37951560 Free article. Clinical Trial.
134 results